Evidence map›Paper›PMID 30127926›Full record

ArticleOncology letters2018

Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis.

Hiroki Harada, Kei Hosoda, Hiromitsu Moriya, Hiroaki Mieno, Akira Ema, Marie Washio, Yoshimasa Kosaka, Masahiko Watanabe, Keishi Yamashita

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hiroki HaradaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Kei HosodaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Hiromitsu MoriyaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Hiroaki MienoDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Akira EmaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Marie WashioDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Yoshimasa KosakaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Masahiko WatanabeDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Keishi YamashitaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The distribution of lymph node metastases, including recurrences, remains elusive in lower thoracic esophageal squamous cell carcinoma (LtESCC). The present study was a retrospective investigation into the optimized lymph node dissection range during LtESCC. Esophagectomies were performed on 163 patients with ESCC between 2009 and 2016, among whom 41 patients with LtESCC were examined. The rates of pathological and potential (including recurrences) metastases to lymph nodes and the prognosis (median, 34 months) were determined. Preoperative Docetaxel, Cisplatin and 5-fluorouracil chemotherapy was administered in >60% of cStage II/III LtESCC. During stage progression, abdominal lymph node metastasis rapidly becomes aggressive in LtESCC and lymph node metastases to the para-aortic area were more dominant than cervical and recurrent laryngeal nerve (RLN) areas. There were few control failures of regional lymph node metastases in LtESCC with surgery, if 1 unique case with cStage III who had metastases and recurrences of multiple lymph nodes during the clinical course was excluded. Defective lymph node dissection around the RLN did not worsen LtESCC prognosis with no RLN palsy. In the context of the potent preoperative chemotherapy and esophagectomy, lymph node dissection of cervical, para-aortic and RLN areas are putatively not mandatory to all LtESCC patients.

Indexed as

Cisplatin and 5-fluorouracilDocetaxelesophageal squamous cell carcinomalower thoracic esophageal carcinomalymph node metastasisrecurrent laryngeal nerve

Identifiers

PMID30127926
PMCPMC6096102
OpenAlexW2809908912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.